Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 13/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617971 | 0.94 | MAP2 (0.46) | MAP2SIRT1SIRT2SIRT3KDM4E | |
| SCHEMBL3616596 | 0.89 | MAP2 (0.46) | MAP2SIRT1SIRT2SIRT3 | |
| SCHEMBL2928734 | 0.89 | MAP2 (0.51) | MAP2SIRT1SIRT2SIRT3TSHR | |
| SCHEMBL2927238 | 0.89 | MAP2 (0.54) | MAP2TSHR | |
| SCHEMBL2927126 | 0.88 | MAP2 (0.59) | MAP2KDM4EHSD17B10 | |
| SCHEMBL2924539 | 0.87 | MAP2 (0.53) | MAP2TSHR | |
| SCHEMBL3609347 | 0.87 | SIRT1 (0.40) | SIRT1KDM4ETSHR | |
| SCHEMBL2923342 | 0.86 | PTGS2 (0.49) | MAP2 | |
| SCHEMBL2923480 | 0.85 | MAP2 (0.48) | MAP2SIRT1 | |
| SCHEMBL2926071 | 0.84 | MAP2 (0.47) | MAP2SIRT1KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1899340-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002368-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | MAP2 2470/4885SIRT1 745/4885SIRT2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.